Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer

Gemcitabine is the standard-of-care for chemotherapy in patients with pancreatic adenocarcinoma and it can directly incorporate into DNA or inhibit ribonucleotide reductase to prevent DNA replication and, thus, tumor cell growth. Most pancreatic tumors, however, develop resistance to gemcitabine. Po...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cell Cycle
Päätekijät: Li, Jie, Wang, Ruixin, Schweickert, Patrick G., Karki, Anju, Yang, Yi, Kong, Yifan, Ahmad, Nihal, Konieczny, Stephen F., Liu, Xiaoqi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2016
Aiheet:
Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4845940/
https://ncbi.nlm.nih.gov/pubmed/26890815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2016.1148838
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia